US 7,473,421 B2
	Humanized anti-CCR2 antibodies and methods of use therefor
Gregory J. LaRosa, Newton, Mass. (US); Christopher Horvath, Taunton, Mass. (US); Walter Newman, Boston, Mass. (US); S. Tarran Jones, Radlett (United Kingdom); Siobhan H. O'Brien, London (United Kingdom); and Theresa O'Keefe, Waltham, Mass. (US)
Assigned to Millennium Pharmaceuticals, Inc., Cambridge, Mass. (US)
Filed on Jan. 27, 2004, as Appl. No. 10/766,773.
Application 10/766773 is a division of application No. 09/497625, filed on Feb. 03, 2000, granted, now 6,727,349.
Application 09/497625 is a continuation in part of application No. 09/359193, filed on Jul. 22, 1999, granted, now 6,352,832.
Application 09/359193 is a continuation in part of application No. 09/121781, filed on Jul. 23, 1998, granted, now 6,312,689.
Prior Publication US 2004/0126851 A1, Jul. 01, 2004
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/00 (2006.01); A61K 39/02 (2006.01)

U.S. Cl. 424—139.1  [435/69.6; 435/5]

23 Claims

1. A method of treating a disorder mediated by activation of CCR2 by binding of a chemokine in a patient, comprising administering to the patient an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2 comprising a heavy chain and a light chain, wherein said light chain comprises three complementarity determining regions of the variable light chain of SEQ ID NO: 9 and a light chain framework region of SEQ ID NO: 11, and wherein said heavy chain comprises three complementarity determining regions of the variable heavy chain of SEQ ID NO: 10 and a heavy chain framework region of SEQ ID NO: 16.